Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease
- 214 Downloads
Purpose of Review
This review will serve to highlight the clinical rationale used in the selection of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) or glucagon-like peptide 1 receptor agonists (GLP1-ra).
SGLT2-i and GLP1-ra are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit in multiple cardiovascular outcomes trials (CVOTs), with benefits that are consistent across class of medication.
Diabetes is a major risk factor for morbidity and mortality from cardiovascular disease. Sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and glucagon-like peptide 1 receptor agonists (GLP1-ra) are the first anti-hyperglycemics to demonstrate significant cardiovascular benefit. Given the unique side effect and benefit profiles, appropriate consideration of these agents with a focus on cardiovascular risk reduction requires an individualized approach.
KeywordsDiabetes Cardiovascular disease Sodium-glucose cotransporter 2 inhibitor Glucagon-like peptide 1 receptor agonist Prevention
Compliance with Ethical Standards
Conflict of Interest
Devinder S. Dhindsa, Anurag Mehta, Pratik B. Sandesara, Aneesha Thobani, Stephen Brandt, and Laurence S. Sperling declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet (London, England) 1998;352(9131):837–53.Google Scholar
- 3.Effects of intensive glucose lowering in type 2 diabetes. 2008;358(24):2545–59.Google Scholar
- 4.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. 2008;358(24):2560–72.Google Scholar
- 5.•• Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28 This study was the first cardiovascular outcomes trial to show a benefit of an anti-hyperglycemic medication in cardiovascular outcomes. Empagliflozin demonstrated a large and surprising benefit in cardiovascular endpoints as compared with placebo. CrossRefGoogle Scholar
- 6.Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. 2017;377(7):644–57.Google Scholar
- 7.Fitchett D, investigators tE-ROt, Zinman B, investigators tE-ROt, Wanner C, investigators tE-ROt, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37(19):1526–34.CrossRefGoogle Scholar
- 9.• Kato Eri T, Silverman Michael G, Mosenzon O, Zelniker Thomas A, Cahn A, Furtado Remo HM, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528–36. This study showed that the benefit of the SGLT2 inhibitors is particularly evident in heart failure with reduced ejection fraction. CrossRefGoogle Scholar
- 12.Dhindsa DS, Sandesara PB, Shapiro MD. The intersection of diabetes and cardiovascular disease—a focus on new therapies. Frontiers in Cardiovascular Medicine. 2018;5:160.Google Scholar
- 14.Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–23.CrossRefGoogle Scholar
- 19.• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–22 This study was the first to show cardiovascular benefit among the GLP1 receptor agonists, showing a reduction in cardiovascular mortality in those randomized to liraglutide as compared with placebo. CrossRefGoogle Scholar
- 21.Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.CrossRefGoogle Scholar
- 23.•• Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease. A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72(24):3200–23. Major statement by the American College of Cardiology urging the consideration and use of SGLT-2 inhibitors and GLP-1 receptor agonists among cardiologists. Google Scholar
- 31.Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004–16.CrossRefGoogle Scholar